

09876543210

**PROTECTION-OF-TELOMERE-1 (POT-1) PROTEIN AND
ENCODING POLYNUCLEOTIDES**

Inventors:

Peter Baumann

Thomas R. Cech

**PROTECTION-OF-TELOMERE-1 (POT-1) PROTEIN AND
ENCODING POLYNUCLEOTIDES**

BACKGROUND OF THE INVENTION

Telomeres are the protein-DNA complexes that protect the ends of linear eukaryotic chromosomes from degradation, prevent end-to-end fusions and partake in chromosome localization and segregation (Cooper, *Curr Opin Genet Dev* 10: 169-77, 2000; McEachern *et al.*, *Annu Rev Genet* 34: 331-358, 2000; Price, *Curr Opin Genet Dev* 9: 218-24, 1999). Telomere length, 15-20 kb in human embryonic or germ line cells, is maintained in part by the enzyme telomerase. In the absence of telomerase activity, about 50-200 bases of DNA are not replicated with each round of cell division, resulting in the eventual diminution in telomere size to typically 5-7 kb. At that length, cells enter a state of arrested growth called replicative senescence. The maintenance of telomere length thus is believed to play a key role in the ability of cells to avoid replicative senescence and to propagate indefinitely, as is the case with stem cells. Likewise, aberrant maintenance of telomere length is believed to underlie indefinite cellular proliferation characteristic of cancer cells (Bodnar *et al.*, *Science* 279: 349-352, 1998; Bryan *et al.*, 1997; McEachern *et al.*, 2000).

Telomeres consist of repeating units of GC-rich DNA and terminate in a single stranded extension of the 3' strand. *Oxytricha nova* telomeres, for example, consist of tandem repeats of (TTTGCGGG) and end with a 16 nucleotide overhang of the G-rich strand. By contrast, human telomeres have a repeating sequence (TTAGGG)_n and end with a 50-100 nucleotide overhang of the G-rich strand. McEachern *et al.*, 2000.

A number of proteins have been identified that specifically interact with the double-stranded portion of the telomere or the single-stranded 3' extension at its very end. Among the most well characterized are the telomere end-binding proteins from hypotrichous ciliated protozoa (Gottschling *et al.*, *Cell* 47: 195-205, 1986; Price *et al.*, *Genes Dev* 1: 783-93, 1987). The α and β subunit of the *O. nova* Telomere

End-Binding Protein (TEBP) bind specifically to the 16 nucleotide single-stranded extension at the ends of macronuclear chromosomes (Gray *et al.*, *Cell* 67: 807-14, 1991) and form a ternary complex whose structure has been determined using X-ray crystallography (Horvath *et al.*, *Cell* 95: 963-974, 1998). Although both protein subunits directly interact with DNA in the ternary complex, only α binds telomeric DNA by itself (Fang *et al.*, *Genes Dev* 7: 870-82, 1993). The DNA binding domain in the α subunit has been mapped to the N-terminal two-thirds of the polypeptide (Fang *et al.*, 1993) and is comprised of two "OB folds" (Horvath *et al.*, 1998). *In vitro* reconstituted α -DNA complexes are substrates for telomerase, whereas α - β -DNA complexes are not; an observation which may indicate a function in the regulation of telomere length (Froelich-Ammon *et al.*, *Genes Dev* 12: 1504-14, 1998).

The protrusion of the G-rich strand as a single-stranded overhang is conserved between ciliates (Klobutcher *et al.*, *Proc Natl Acad Sci U S A* 78: 3015-19, 1981), yeast (Wellinger *et al.*, *Cell* 72: 51-60, 1993) and mammalian cells (Makarov *et al.*, *Cell* 88: 657-66, 1997; McElligott *et al.*, *Embo J* 16: 3705-14, 1997; Wright *et al.*, *Genes Dev* 11: 2801-09, 1997), suggesting the existence of similar functional mechanisms in telomere maintenance. However, proteins sharing sequence homology with ciliate TEBPs were not identified in the complete *S. cerevisiae* genome or among the proteins that bind single-stranded telomeric DNA *in vitro*. Similarly, the *S. cerevisiae* single-stranded telomeric DNA-binding protein cdc13p has not been proposed to be homologous to the ciliate TEBPs, nor have cdc13p homologues been identified in distantly related species. (Ishikawa *et al.*, *Mol Cell Biol* 13: 4301-10, 1993; Lin *et al.*, *Proc Natl Acad Sci U S A* 93: 13760-65, 1996; McKay *et al.*, *Nucleic Acids Res* 20: 6461-64, 1992; Nugent *et al.*, *Science* 274: 249-52, 1996; Virta-Pearlman *et al.*, *Genes Dev* 10: 3094-104, 1996).

The apparent absence of specific end-capping proteins in some eukaryotes has been explained by the adoption of a telomere structure distinct from that found in the macronuclei of hypotrichous ciliates. This telomere structure, found at the ends of

P002540614.4

mammalian and *O. fallax* chromosomes, is a large duplex loop, or “t loop,” created by the sequestration of the single-strand overhang within the double-stranded portion of the telomeric tract (Griffith *et al.*, *Cell* 97: 503-14, 1999; Murti *et al.*, *Proc Natl Acad Sci U S A* 96: 14436-39, 1999). In mammals, this architecture is believed to be maintained by a number of proteins, including the TTAGGG-binding factors, TRF1 and TRF2. TRF2 is believed to catalyze the sequestration of the single-stranded DNA into the duplex region of the DNA. Consistent with this notion is the observation that TRF2 can cause telomeric DNA to form t loops *in vitro* (Griffith *et al.*, 1999). Other proteins have been implicated in telomere architecture and regulation, including TIN2, which was identified by its ability to interact with TRF1 (Kim *et al.*, 1999).

The ability to manipulate telomere structure and metabolism depends on the identification of those components required for the regulation of telomere structure. Evidence has accumulated that telomerase activity itself is not determinative of telomere elongation or replication. For example, some cancer cell lines maintain telomeres in the absence of telomerase activity (Bryan *et al.*, 1997). There is thus a pressing need in the art to identify the functional components that regulate telomere metabolism, to identify compounds that can be used to control the entry, avoidance, or exit of a cell from a state of replicative senescence. Such compounds may be useful alternatively in allowing the indefinite propagation of useful cell lines or in halting the growth of cancer cells *in vivo* for therapeutic purposes.

SUMMARY OF THE INVENTION

The present invention addresses this need by providing a protein that caps the very ends of human chromosomes, and a related protein that caps the ends of chromosomes in fission yeast (*Schizosaccharomyces pombe*). The protein of the invention is termed “Protection of Telomere-1,” or “Pot1p,” or “Pot1 protein.” Specific embodiments of these proteins are those isolated from humans and fission

yeast, hPot1p and SpPot1p, respectively. Polynucleotides encoding a Pot1 protein are also provided.

The inventors have found that Pot1p binds single-stranded telomeric DNA, which is an unforeseen finding, given the apparent absence of end-capping proteins in some eukaryotes. Pot1p both stabilizes chromosome ends and regulates telomerase activity. Accordingly, compounds that stabilize or disrupt the Pot1p-DNA interaction will be useful in regulating the telomere length of a target cell or cell population. The invention thus provides a means of altering cellular life-span, for the purpose of either prolonging the life-span of useful cell populations or making cancer cells enter replicative quiescence. Useful compounds with these properties can be identified through screening methods made possible by the discovery that a Pot1 protein binds single-stranded telomeric DNA. The identification of a Pot1 protein and its encoding DNA also provides a means of developing tools to diagnose illnesses such as cancer that may involve altered expression or structure of a Pot1 protein or gene. Such tools include polynucleotide hybridization probes and antibodies specific for a Pot1 protein.

Accordingly, the invention provides isolated Pot1 proteins having the sequence set forth in SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:9, or SEQ ID NO:11. Variants of these proteins are capable of binding single-stranded telomeric DNA and have at least 85% sequence identity with, or differ by no more than about 20 single amino acid substitutions, deletions or insertions from, a sequence set forth in SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:9, or SEQ ID NO:11. The invention also provides an isolated, naturally occurring, variant of a protein having the sequence set forth in SEQ ID NO:13 or in SEQ ID NO:9, which may be a splicing variant. Fragments of the Pot1 proteins of the invention are capable of binding single-stranded telomeric DNA, and comprise the polypeptide having the sequence set forth in SEQ ID NO:5 or SEQ ID NO:6.

The invention further provides an isolated non-genomic polynucleotide encoding one of the aforementioned proteins. A vector comprising such a

polynucleotide and a host cell comprising the vector also are provided. The polynucleotide may be included in a pharmaceutical composition, along a pharmacologically acceptable excipient, diluent, or carrier. A method of detecting or measuring the presence of a *POT1* polynucleotide comprises contacting the a *POT1* polynucleotide, or its complement, with a biological sample from an individual.

An antibody, or a fragment or variant thereof, is provided, which is capable of binding a Pot1 protein. A method of raising the antibody comprises isolating the antibody from an animal or isolating an antibody-producing cell from an animal, following administration of a Pot1 protein, or an antigenic fragment thereof, to the animal. An antibody of the invention may be useful in detecting or measuring the presence of a Pot1 polypeptide in an individual, by contacting the antibody with a biological sample from an individual.

The invention provides a method of increasing the life-span of a cell, by inserting a vector comprising a *POT1* polynucleotide into the cell, where the *POT1* polynucleotide is operably linked to a promoter that allows the polynucleotide to be transcribed. The vector comprising a *POT1* polynucleotide may be administered to an individual in a pharmaceutical composition, comprising the polynucleotide and a pharmacologically acceptable excipient, diluent, or carrier. In one embodiment, the carrier is capable of preferentially delivering the polynucleotide to a specific cell population. In another embodiment, the vector comprising the *POT1* polynucleotide is inserted into the cell *in vitro*, which then may be subsequently administered to an individual. The target cell may express a second polynucleotide that encodes an exogenous protein, such as a therapeutically useful protein.

A method of identifying a compound that interferes with the binding of a Pot1 polypeptide to single-stranded telomeric DNA comprises determining whether the candidate compound decreases the binding of the Pot1 polypeptide to a single-stranded telomeric DNA molecule in a mixture of the single-stranded telomeric DNA

molecule, the polypeptide, and the candidate compound. The compound identified by this method may be formulated in a pharmaceutical composition.

A method of decreasing the life-span of a cell comprises reducing the level of Pot1p activity in a cell. The cell may be an immortal cell line, such as a cancer cell. In one embodiment, the method comprises delivering one of the compounds that interferes with the binding of a Pot1 polypeptide to single-stranded telomeric DNA.

BRIEF DESCRIPTION OF THE FIGURES

FIGURE 1A: Multiple sequence alignments of the N-terminal regions of yeast and human Pot1p and the α subunits of ciliate TEBPs (Ec, *Euplotes crassus* [SEQ ID NO:1]; Sm, *Styloynchia mytilis* [SEQ ID NO:2]; Ot, *Oxytricha trifallax* [SEQ ID NO:3]; On, *Oxytricha nova* [SEQ ID NO:4]; Hs, *Homo sapiens* [SEQ ID NO:5]; Sp, *Schizosaccharomyces pombe* [SEQ ID NO:6]). The numbers of the first and last amino acid shown are depicted at the beginning and end of each sequence. Sequences were aligned in ClustalW using the Blosum35 score table followed by manual adjustment. Shaded amino acids are conserved in 4 or more sequences.

FIGURE 1B: Domain structure of the *O. nova* TEBP and yeast and human Pot1p. Position of OB folds (Horvath *et al.*, *Cell* 95: 963-74, 1998) and functional domains (Fang *et al.*, *Genes Dev* 7: 870-82, 1993) are depicted for the *O. nova* TEBP. The position of the regions aligned in FIGURE 1A are indicated by open boxes.

FIGURE 1C: Morphological phenotype associated with deletion of *pot1⁺*. Colony morphology of *pot1⁺*, *pot1⁻*, *trt1⁺* and *trt1⁻* following tetrad dissection and germination.

FIGURE 1D: Phase contrast micrographs of *pot1⁺* and *pot1⁻* cells 5 to 10 generations after germination.

FIGURE 1E: Cells as in FIGURE 1D but stained with DAPI to reveal chromosome segregation defect in *pot1⁻*.

46260 46261 46262 46263 46264 46265

FIGURE 2A: Telomere phenotype in *pot1* strains. Genomic DNA from the indicated diploid and haploid strains was digested with *Eco* RI, which cleaves *S. pombe* DNA about 1.0-1.2 kb from the chromosome ends, and then fractionated by 1.1% agarose gel electrophoresis, transferred to a nylon membrane and hybridized to a telomeric probe. A probe against the single-copy *polα* gene was used as a loading control.

FIGURE 2B: Genomic DNA was digested with *Nsi*I, fractionated by 0.8% agarose gel electrophoresis, transferred to a nylon membrane and hybridized to a probe against Telomere Associated Sequences internal to the telomere itself (TAS2 sequences).

FIGURE 2C: The blot shown in FIGURE 2B was stripped and hybridized to a probe against Telomere Associated Sequences that are internal to TAS2 (TAS3 sequences).

FIGURE 3A: DNA-binding specificity of *S. pombe* Pot1p, using conditions described in the Examples. SpPot1p was incubated with the indicated DNA substrates. Complexes were analyzed by nondenaturing gel electrophoresis. The SpPot1p-DNA complex is indicated by an open arrow.

FIGURE 3B: Same as FIGURE 3A except that the added protein contained truncated Pot1p as well as full length protein. Truncated Pot1p-DNA complex is indicated by a closed arrow.

FIGURE 4A: Expression of *hPOT1* and DNA-binding. RT-PCR amplification of *GAPDH* and *hPOT1* mRNA in various human tissues.

FIGURE 4B: Binding of hPot1p to human C-strand (CCCTAA)₅, G-strand (TTAGGG)₅ and duplex (CCCTAA)₅•(TTAGGG)₅. Binding conditions and analysis were as described in FIGURE 3.

Sub
AI

FIGURE 5A: Substrate specificity of *S. pombe* and human Pot1p. Binding of SpPot1p to *S. pombe* and human G-strand DNAs.

FIGURE 5B: Binding of SpPot1p (50 ng) to radiolabeled *S. pombe* G-strand (1.5 fmol, or 1 ng) in the presence of 10-, 100-, and 1000-fold excess of unlabeled competitor *S. pombe*, human or *O. nova* G-strand DNAs.

FIGURE 5C: Binding of hPot1p to *S. pombe* and human G-strand DNAs.

FIGURE 5D: Binding of hPot1p to human G-strand DNAs under same conditions as in FIGURE 5B.

FIGURE 6: Inhibition of telomerase activity by Pot1p. Telomerase activity is assayed with telomeric primer PBoli82 (TGTGGTGTGTGGGTGTGC) as described in Haering *et al.*, *Proc. Nat'l Acad. Sci. USA* 97: 6367-72, 2000. Unlabeled nucleotides are added to a concentration of 100 μ M as follows: lanes a and b, dATP, dCTP and dTTP; lanes c and d, ddATP, dCTP and dTTP; lanes e and f, dATP, dCTP and ddTTP. For lanes b, d, and f the oligonucleotide was preincubated with a SpPot1p preparation containing full length protein and the N-terminal 22 kDa fragment (100 ng/ μ l). The Pot1 protein inhibits primer extension by telomerase.

FIGURE 7: *S. pombe* *POT1* genomic DNA. The sequence shown (SEQ ID NO:7) is published by the Sanger Centre as part of cosmid c26H5, having accession number SPAC26H5. The sequence contains an upstream promoter sequence, a coding sequence, which includes two introns, 1 and 2, and a downstream terminator sequence.

FIGURE 8A: A *S. pombe* *POT1* cDNA sequence (SEQ ID NO:8), in which both introns 1 and 2 have been spliced out.

FIGURE 8B: A SpPot1 protein (SEQ ID NO:9) encoded by the DNA sequence of SEQ ID NO:8.

FIGURE 8C: A splicing variant of the *S. pombe* *POT1* cDNA sequence of SEQ ID NO:8, in which intron 2 has not been spliced out (SEQ ID NO:10)

002540614.4

FIGURE 8D: The SpPot1 polypeptide (SEQ ID NO: 11) encoded by the splicing variant of SEQ ID NO:10.

FIGURE 9A: A full-length *hPOT1* cDNA (SEQ ID NO:12).

FIGURE 9B: The hPot1p splicing variant (SEQ ID NO:13) encoded by the polynucleotide of SEQ ID NO:12.

FIGURE 9C: Another splicing variant of *hPOT1* cDNA (SEQ ID NO:14), having an inserted exon indicated by the underlined residues.

FIGURE 9D: The hPot1p splicing variant (SEQ ID NO:15) encoded by the polynucleotide of SEQ ID NO:14. The alternatively spliced exon gives rise to a protein that is about 50% shorter than full-length hPot1p and has an alternative C-terminus.

FIGURE 9E: A splicing variant of *hPOT1* cDNA (SEQ ID NO:16). An exon is skipped, giving raise to a hPot1p with an alternate C-terminus.

FIGURE 9F: The hPot1p splicing variant (SEQ ID NO:17) encoded by SEQ ID NO: 16.

FIGURE 10A-F: A partial genomic clone of *hPOT1* (AC004925; SEQ ID NO:18). Exons are in capital letters.

FIGURE 10G: A scale diagram of SEQ ID NO:18, showing the relative position of exons. Exons are numbered arbitrarily, because the clone does not extend to the 5' end of the gene. The exons present in the splicing variants of FIGURE 9 are indicated. "Splice variant #1" corresponds to SEQ DI NO:13, "Splice variant #3" corresponds to SEQ ID NO:15, and "Splice variant #3" is SEQ ID NO:17.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The inventors provide a method to control the life-span of a cell. The life-span of a cell depends in part on the ability of a cell to replicate its telomeres with

each round of cell division. A Pot1 protein stabilizes chromosomes by binding the single-strand G-rich 3' extension in the telomere, thereby avoiding loss of telomeric DNA and concomitant chromosome fusion or degradation. In the presence of a telomere replication mechanism, such as telomerase or telomeric recombination, Pot1p allows cells to undergo repeated division without reduction in the length of the telomere and attainment of replicative senescence. The isolation of a Pot1 protein and its encoding polynucleotide allows a method of screening for compounds that affect the interaction between Pot1p and telomeric DNA. These compounds will be useful in prolonging or reducing the life span of a cell or population of cells.

The existence of end-capping proteins in humans and *S. pombe* was unforeseen, given the previous inability to find such proteins. The inventors found that *S. pombe* open reading frame SPAC26H5.06 contains a region of modest sequence similarity to the α subunits of TEBP from *Oxytricha nova* and other ciliates (FIGURE 1A). Conservation is most apparent over a 95 amino acid stretch near the N-termini of the proteins where the *S. pombe* and *O. nova* sequences share 19% identity and 40% similarity. This region coincides with the most highly conserved domain within the ciliate sequences (42% amino acid identity [61% similarity] between *O. nova* and *E. crassus*). Sequence alignments of hPot1p with the *S. pombe* protein reveals the highest conservation near the N-terminus where the *S. pombe* and human proteins share 48% similarity (26% identity) (FIGURE 1A). Over the same region, the similarity of the human sequence with the *O. nova* protein is 39% (23% identity). Such levels of similarity and identity are often found between functionally unrelated proteins, so they are insufficient to indicate homology; therefore, tests of function were performed. No obvious sequence similarity by primary sequence alignment is noted between hPot1p or SpPot1p and cdc13p, the single-stranded telomeric DNA-binding protein of *S. cerevisiae*.

002540614.4

Pot1 proteins prevent chromosomal instability.

The inventors demonstrate by gene knock-out a role of the *S. pombe* gene, *pot1*⁺, in telomere maintenance. A heterozygous diploid *pot1*⁺/*pot1*⁻ *S. pombe* was constructed by the method described in Baumann and Cech, *Mol Biol Cell* 11: 3265-75, 2000. Tetrad dissections revealed that the *pot1*⁻ daughters formed only very small colonies compared to their *pot1*⁺ sisters (FIGURE 1C). This immediate phenotype is in stark contrast to the observations made with strains lacking the catalytic subunit of telomerase (*trt1*), which form wild-type sized colonies upon sporulation (FIGURE 1C) and only begin to show a growth defect on the third re-streak, when telomeres have shortened considerably (Nakamura *et al.*, *Science* 282: 493-96, 1998). For approximately 10 generations after sporulation, *pot1*⁻ colonies contained a large number of elongated cells, most of which failed to undergo further divisions (FIGURE 1D). DAPI staining revealed a high incidence of chromosome missegregation, often leading to daughter cells without any chromosomal DNA (FIGURE 1E).

By deleting the *S. pombe* *pot1*⁺ gene, the inventors have shown that a Pot1 protein plays a pivotal role in preventing instability of chromosome ends *in vivo*. Biochemical and structural data have suggested a role for the *Euplotes* and *Oxytricha* TEBPs in protecting the very ends of chromosomes; however, because these organisms are not amenable to genetic studies, proof of such a capping function *in vivo* has been lacking. This proof is now provided by deletion of the *pot1*⁺ gene, which leads to immediate chromosome instability (FIGURE 2). Telomeres could not be detected by Southern blotting of genomic DNA from *pot1*⁻ strains (FIGURE 2A). Using three DNA probes that recognize distinct subregions of the telomere associated sequence (TAS), hybridization signals were only observed with the telomere distal TAS3 probe (FIGURE 2C), but not with TAS1 or TAS2 (FIGURE 2B and data not shown). These results indicate that around 5 kb of terminal sequence had been lost within ~30 generations after loss of *pot1*⁺.

DE200207060

In contrast to the immediate chromosome instability caused by an absence of functional SpPot1p, the absence of functional telomerase causes gradual telomere shortening over many generations without an immediate effect on chromosome stability and cell viability (Nakamura *et al.*, 1998). Thus, at least in *S. pombe*, Pot1p apparently is more important for telomere maintenance in the short term than telomerase.

Pot1 proteins specifically bind single-stranded telomeric DNA.

Pot1 proteins bind directly to single-stranded telomeric DNA. The SpPot1 protein was expressed and purified from *E. coli*, using methodology described below, and the ability of the expressed protein to bind DNA was assayed using an electrophoretic mobility shift assay. SpPot1p interacts specifically with the G-rich strand of *S. pombe* telomeric DNA, but not with the complementary C-rich strand or double-stranded telomeric DNA (FIGURE 3A).

N-terminal fragments of the SpPot1 protein maintain the ability to bind single-stranded telomeric DNA. Several truncated forms co-eluted with the full length protein from the Ni-NTA column used to purify the expressed SpPot1 protein. These polypeptides retain the N-terminal His₆ tag and thus are believed to arise either from premature termination or from proteolytic degradation of SpPot1p. These truncated proteins had a higher affinity for DNA while retaining the same specificity as displayed by the full length protein (FIGURE 3B). Titration experiments indicated that the apparent K_d for binding of a predominant N-terminal fragment of Pot1p to the G-rich oligo is approximately 10 fold higher than for the full length protein (10 nM versus 100 nM). Further purification and analysis by mass spectroscopy showed that the strong shift (indicated by a closed arrow in FIGURE 3B, lane d) is attributable to the binding of a 22 kDa N-terminal fragment of SpPot1p. Increased DNA binding likewise has been observed with N-terminal fragments of the α subunit of TEBP from *Oxytricha nova* (Fang *et al.*, 1993).

hPot1p N-terminal fragments show the same behavior as SpPot1p fragments. hPot1p, like SpPot1p, often lacks C-terminal sequences due to degradation or premature termination. These truncated forms of hPot1p also show the same DNA binding specificity as full length hPot1p obtained from *in vitro* translation reactions. In gel shift assays, hPot1p binds G-rich strands of human telomeric DNA (FIGURE 4B). As with SpPot1p, binding was not observed with the complementary C-rich strand or with double-stranded telomeric DNA.

SpPot1p and hPot1p both bind specifically to telomeric DNA. That is, binding of both SpPot1p and hPot1p was unaffected by the presence of a 60-fold excess of herring sperm DNA and 2000-fold excess of an oligonucleotide of non-telomeric sequence. To further investigate the sequence specificity, G-rich strands of telomeric DNA from different species were tested as substrates in DNA-binding assays. In a side-by-side comparison, SpPot1p bound the human telomeric sequence (GGGTTA repeat) with a lower affinity than the *S. pombe* telomeric sequence (repeating units of the consensus sequence GGTTACA) (FIGURE 5A). In competition experiments, a 1000-fold excess of unlabeled *S. pombe* sequence abolished binding to the radiolabeled substrate, whereas the human and *O. nova* DNA competitors reduced binding by only ~50% and < 2%, respectively (FIGURE 5B). Similarly, hPot1p showed only weak binding to the *S. pombe* sequence (FIGURE 5C), which also was not an efficient competitor (FIGURE 5D). In contrast, the presence of a 1000-fold excess of the *O. nova* sequence reduced binding to less than 25%. Accordingly, both SpPot1p and hPot1p specifically bind telomeric DNA, and each shows a higher affinity for telomeric DNA from their own species.

Pot1p binds a variety of related telomeric DNA sequences. Oligonucleotides that form a DNA-Pot1p complex, as determined by an electrophoretic mobility shift assay, are shown in Table I, below. The affinity between Pot1p and the oligonucleotide varies with the particular sequence (data not shown).

TABLE I

SpPot1p-binding oligonucleotides:

Sub A3

PBoli52	GGT TAC GGT TAC AGG TTA CA
PBoli53	CGG TTA CAC GGT TAC AGG T
PBoli54	GTT ACA GGT TAC GGT TAC GG
PBoli86	TGT GGT GTG TGG GTG TGC GGT T
PBoli110	GGT TAC ACG GTT ACA GGT TAC AGG TTA CAG
PBoli112	GGT TAC ACG GTT ACA GGT TAC AGG TTA CAG GGT TAC G
PBoli183	CTG TAA GCA TAT CAT CAT TCG A GGT TAC
PBoli184	GGT TAC GCA TAT CAT CAT TCG A ATC TCG
PBoli185	CTG TAA GCA TAT CAT CGG TTA CGG TTA C
PBoli186	GGT TAC GGT TAC CAT CAT TCG A ATC TCG
PBoli187	CTG TAA GCA TAT GGT TAC TCG A ATC TCG
PBoli188	CTG TAA GC GGT TAC GGT TAC GA ATC TCG
PT1	GGT TAC AGG TTA CAG GTT AC

hPot1p-binding oligonucleotides:

PBoli177	TTA GGG TTA GGG TTA GGG TT
PBoli178	GG TTA GGG TTA GGG TTA GGG
PBoli179	TTA GGG TTA GGG TTA GGG TTA GGG TTA GGG

hPOT1 mRNA is detected in all tissues examined, although a high steady-state level of *hPOT1* mRNA is observed in testis and lower levels are observed in colon, skeletal muscle, and peripheral blood lymphocytes (FIGURE 5A and data not shown). In contrast with mRNA levels of human *TERT*, which correlate with cellular immortality and proliferative activity, the presence of *hPOT1* mRNA in all tissues examined is consistent with *hPOT1* being a house keeping gene, required to ensure the integrity of chromosome ends independently of the proliferative state of cells.

Screening methods to identify useful compounds that affect the interaction of Pot1p with single-stranded telomeric DNA.

The use of routine screens to find inhibitors and activators of Pot1p is facilitated by providing a polynucleotide that encodes a Pot1 protein, which allows Pot1p to be expressed recombinantly. Pot1p thus may be expressed *in vitro* or in a host cell, such as *E. coli*, yeast, or baculovirus-infected insect cells, and tested against candidate compounds. Useful compounds will be those that affect the binding between a Pot1 polypeptide and telomeric DNA, especially the G-rich single-stranded component.

The interaction between Pot1p and telomeric DNA is readily assayed *in vitro*, by a number of routine methods that are well known to the artisan. *In vitro* assays can be configured as high throughput assays, to test candidate molecules simultaneously. In one embodiment, such assays can be designed around the electrophoretic mobility shift assays described in the examples.

Candidate molecules that will be useful for the invention generally will include small organic compounds that interact with a Pot1 protein or a Pot1 protein-DNA complex to change the binding constant. In one embodiment, candidate molecules are rapidly identified by their ability to change the amount of labeled probe that interacts with a Pot1 protein *in vitro*. Candidates with possible activity are then further analyzed to determine an apparent binding constant, which is compared to that of the control reaction lacking a candidate molecule, to determine whether the particular compound strengthens or weakens the interaction between Pot1p and the telomere. Promising candidates may be subsequently analyzed in a cell culture system, to analyze the effect of the candidate molecule on telomere length or integrity throughout repeated cell divisions. The examples describe a number of tests that can be used to assay the role of Pot1p on telomere structure.

Likely candidate compounds that will inhibit the interaction between a Pot1 polypeptide include compounds that can act as a substrate analogue. Since the substrate for a Pot1 protein is telomeric DNA, such compounds include single-

P00240034560

stranded DNA comprising TTAGGG repeats, when used to inhibit a hPot1 protein or single-stranded DNA comprising GGTTACA repeats, when used to inhibit a SpPot1 protein. FIGURE 5B, lanes d-e, and FIGURE 5D, lanes g-h and k provide *in vitro* proof of principle of the efficacy of such inhibitors. The oligonucleotides listed in TABLE I represent a variety of useful compounds with a known ability to act as substrate analogues. Thus, these oligonucleotides themselves, or analogues of these oligonucleotides with advantageous pharmacological properties, will be useful compounds for the inhibition of Pot1p activity.

Preferred analogues of these oligonucleotides are non-hydrolyzable DNA analogues that have increased pharmacological longevity and efficacy. One DNA analogue with enhanced stability relative to DNA is a peptide nucleic acid (PNA) molecule that comprises a Pot1 protein binding site. Such molecules, along with methods of their formulation and delivery, are generally described in U.S. Pat. No. 6,046,307.

Candidate molecules that will be useful for the invention may also include small organic compounds that modulate telomerase activity. These compounds may be administered in combination with compounds that regulate Pot1p activity. Alternatively, these compounds themselves are candidates for regulators of Pot1p activity, and their possible effect on Pot1p activity can be determined by the screening methods of the invention. These compounds are described in U.S. Pat. Nos. 6,194,206, 6,156,763, 6,110,955, or 6,054,442, for example.

Methods to extend the life-span of cells.

The inventors have shown that chromosome of cells lacking Pot1p activity are susceptible to rapid disorganization and destabilization. Pot1p thus maintains telomere structure and function, which provides a means of therapeutic intervention in cases where it is desirable to alter telomere structure and function. Methods are provided alternatively to stabilize or to destabilize telomere structure, depending on the desirability of prolonging the proliferative capacity, or life-span, of the cell in

question. "Proliferative capacity" and "life-span" both are used in this context in terms of how many times a cell can divide before it enters replicative senescence.

Enhancing the activity of a Pot1 protein in a cell advantageously can stabilize telomeres and thereby prolong the life-span of the cell. Examples of suitable target cells include those that are genetically engineered to produce a desired protein or those that produce useful antibodies. Other desirable target cell types include isolated stem cells, especially where disease otherwise would deplete various stem cell populations. Additional advantageous target cells include cells that proliferate in response to repeated tissue injury, such as endothelial cells, or cells whose functions are susceptible to aging or disease, such as CD4+ cells, connective tissue fibroblasts, or cells affected by age-related macular degeneration.

Pot1p activity can be increased in a number of ways in these desired target cells. In one method, Pot1p activity is increased by transfecting the cell with an expression construct that encodes a Pot1 protein. In this embodiment, the "effector compound" is an expression vector that directs high level or regulated expression of a Pot1 polypeptide. The expression causes higher levels of Pot1p to accumulate in the target cell, thereby increasing the overall level of Pot1p activity or replacing Pot1p lost through genetic mutation. In another method, the cell is treated with a small effector compound that stabilizes the interaction between Pot1p and telomeric DNA. In either case, the effector compound may be added to a cell *ex vivo* to affect Pot1p expression, followed by administration of the cell to the individual undergoing treatment. Alternatively, the effector compound may be administered to the cell *in vivo*. In this case a preferable means of administration directs or targets the effector compound to the desired cell. Suitable means of cell targeting are known in the art, and include liposome encapsulation and antibody-directed targeting, or combinations of these two.

In some instances, it may be desirable to increase Pot1p expression temporarily. When an effector compound is administered *in vivo*, this control typically can be achieved simply by discontinuing administration. Where Pot1p

expression is increased through recombinant engineering, on the other hand, it may be desirable to control Pot1p expression with an inducible or regulated promoter. Expression then can be induced for as long as desired by administering the appropriate inducer or regulatory compound.

By contrast, an inhibitor of Pot1 protein function will be useful in shortening the life-span of cells, whose presence is undesirable, through the destabilization of telomere structure and function. Such cells include those that are immortalized by aberrant expression of telomerase, as in many cancer cell lines. Inhibitors may be delivered to the entire body, as is currently common in chemotherapeutic methods. Because Pot1p is expressed in a variety of cell types in humans, and may be expressed ubiquitously, the amount of administered inhibitor must be carefully monitored to prevent adverse side-effects to other non-targeted cell types that express Pot1p. As an alternative or supplement to whole-body delivery, localized delivery may be employed. For example, inhibitors can be formulated as a depot for internal delivery to the site of a tumor. In another embodiment, inhibitors may be targeted to a specific population of cells by one of the many available means of cell targeting, such as immunotargeting.

Parasitic or pathogenic cells, *e.g.* yeast, whose proliferation or life-span may be controlled by regulating telomere length, also are desirable targets for Pot1p inhibitors. Accordingly, one embodiment of the invention is a method of controlling yeast infection through administration of a therapeutically effective amount of a Pot1p inhibitor.

FIGURE 6 demonstrates the ability of Pot1p to inhibit telomerase action. Pot1p is believed to inhibit telomerase activity through the formation of a Pot1p-telomeric DNA complex. Compounds which strengthen or weaken this complex thus are expected to affect the level of telomerase activity in a cell. In one embodiment of the invention, a method in which Pot1p activity is increased in a cell, such as by recombinant expression of a *POT1* polynucleotide, is combined with the administration of a compound that inhibits telomerase activity. A variety of

002540614.4

telomerase inhibitors are known in the art, as described in U.S. Pat. No. 6,156,763, for example.

Pot1 polypeptides.

The skilled artisan will appreciate that useful variants of a Pot1 protein include those that maintain the capability of binding single-stranded telomeric DNA. These variants will be useful, for example, in methods of screening for compounds that affect the ability of a Pot1 protein to interact with single-stranded DNA. Other useful protein variants may not exhibit DNA-binding activity, but may be useful for other purposes. Such purposes include raising antibodies that specifically bind a Pot1 protein, such as a non-functional, naturally occurring mutation of Pot1p. Such purposes also include the identification of dominant negative inhibitors that bind other cellular proteins that normally interact with Pot1p. Variants may occur naturally or may be created by modifying the primary sequence of the protein through manipulation of a polynucleotide encoding a Pot1 protein. “Protein” and “polypeptide” are used interchangeably throughout.

“Variants” of an hPot1 and SpPot1 protein include naturally occurring allelic variations of hPot1p and SpPot1 proteins, a fragment of a Pot1 protein that binds single-stranded telomeric DNA, or a fragment thereof that elicits an antigenic response when administered to a host animal. Variants also include polypeptides that have a modified amino acid sequence from the aforementioned polypeptides. Because protein function depends on three-dimension structure, skilled artisan will recognize that variants bearing the closest structural relationship to hPot1p and SpPot1p are most likely to preserve biological function. Sequence modifications include amino acid substitutions, insertions, and deletions. Amino acid insertions and deletions may be made in the interior of the protein sequence, as well as at the amino and carboxyl termini. Guidance in determining which and how many such sequence modifications may be made without abolishing biological or antigenic activity may be found using computer programs well known in the art, for example, DNASTar software.

The sequence of variants preferably will have an 80% identity to the full-length hPot1p and SpPot1 proteins. More preferably, variants will have at least about 85% identity to the full-length sequences. Even more preferably, the percent identity will be at least about 90%, and most preferably, the percent identity will be at least about 95%, or even 98%. Likewise, variants of fragments of hPot1p and SpPot1 proteins will be useful for the invention, for instance, as antigenic fragments. Such variants will have at least about 85% identity to fragments of the hPot1p and SpPot1 proteins. Even more preferably, the percent identity will be at least about 90%, and most preferably, the percent identity will be at least about 95%, or even 98%. Preferably, antigenic fragments will be 5, 10, 15, 20, or 30 amino acids in length. A preferred biologically active Pot1p fragment folds into DNA-binding domain. Biologically active fragments include the N-terminal fragments of Pot1p identified by gel shift assays, including the 22 kDa fragment of SpPot1p.

Variants may also include “**splicing variants**.” It is well-known that, within a given eukaryotic gene, sequences that encode the polypeptide gene product are non-contiguous. The protein coding sequences, or exons, are divided by intervening non-coding sequences, known as introns. These introns are transcribed but then spliced out during maturation of the mRNA. Exons often correspond to functional domains of the protein product. Go, *Nature* 291:90-92 (1981); Branden *et al.*, *EMBO J.* 3:1307-10 (1984).

Exons themselves may be spliced out during the maturation of the mRNA. In some cases, two exons may be mutually exclusive in the mature mRNA. Deletion or swapping of exons is known as alternative splicing. Andreadis *et al.*, *Ann. Rev. Cell Biol.* 3:207-42 (1987). The family of proteins produced by alternatively spliced mRNAs exhibit different functional properties, depending on which exons are present in the mature mRNA. Typically, alternative splicing is regulated in a tissue-specific manner and involves only one or a few exons within a gene.

Thus, the polynucleotides of the invention encompass variants that differ by the addition, deletion or alternative splicing of exons. In general, exons alternatively

Sub A

added to the 5' or 3' termini of the open reading frame are encompassed by "addition" variants, whereas alternatively spliced exons that contribute additional coding sequences within the open reading frame are encompassed by "insertion" variants.

Specific splicing variants encompassed by the invention are shown in the Figures. The *SpPOT1* gene, for example, has two introns, which normally are spliced from the mature transcript. However, in one splicing variant, intron 2 may not be spliced, so that it is included in the mature transcript (SEQ ID NO:10). Because the intron does not contain a stop codon, the splicing variant mRNA gives rise to a somewhat larger polypeptide (compare SEQ ID NO:9 and 11). When intron 1 is not spliced out, however, the resulting protein is truncated as a result of a stop codon within intron 1. The resulting peptide has the sequence: M G E D V I D S L Q L N E L L N A G E Y K I G V R Y Q W I Y I C F A N N E K G T Y I S V H. Alternatively, translational frame shifting may lead to a significantly larger protein product. Translational frame shifting has been observed in a number of proteins involved in telomere metabolism. Aigner *et al.*, *EMBO J.* 19: 6230-39, 2000. Polypeptides resulting from translational frame shifting also are considered "splicing variants" for the purposes of the invention.

A more complex pattern of splicing variants is observed in *hPOT1* polynucleotides. In one splice variant, exon 5 is not incorporated into the mature transcript (see FIGURE 10G for nomenclature). The resulting polypeptide is 72 kDa in size and is shown in FIGURE 9B (SEQ ID NO:13). When exon 5 is included in the mature transcript, the resulting protein is an N-terminal fragment that is 38 kDa in size, because of the presence of a stop codon within exon 5 (SEQ ID NO:15). When the mature transcript lacks exons 5 and 10, it gives rise to another N-terminal fragment 58 kDa in size. Additional variants may arise from translational frame shifting, as well.

Additional polypeptide sequences or other moieties, such as covalently attached detectable tags, may be added to the proteins of the invention. Additional polypeptide sequences may fused to either the amino or carboxyl termini of the polypeptides of the

TOP SECRET//SI

invention, and they may be useful, for example, in assisting the expression, purification, and/or detection proteins of the invention. For example, these various sequences include those well known in the art that are useful in purification of recombinantly expressed proteins. A preferred fusion protein, which the inventors have reduced to practice, comprises a "His₆ tag" sequence, which facilitates purification of the recombinantly expressed protein. A preferred purification system is the TALON™ nondenaturing protein purification kit for purifying His₆-tagged proteins under native conditions (CLONTECH, Palo Alto, CA).

"Isolated" polypeptides of the invention have been purified to remove at least some portion of cellular or non-cellular molecules with which the proteins are associated naturally. Isolated proteins include those that are partially purified or enriched, as well as those purified to homogeneity. Isolated proteins also include those produced artificially, such as by recombinant expression or by *in vitro* translation. The isolated protein may be included in compositions containing other polypeptides for specific purposes, for example, as stabilizers.

"Substitutions, insertions, additions and deletions" refer to changes in a particular polypeptide sequence, or any one its naturally occurring splicing variants. "Substitutions" generally refer to alterations in the amino acid sequence that do not change the overall length of the polypeptide, but only alter one or more amino acid residues, substituting one for another in the common sense of the word. Generally speaking, the number of amino acid substitutions for any given variant will not be more than about 20, 10, 5, or 3, such as 1-20 or any range or value therein. Substitutions preferably are conservative, such that one amino acid is replaced with one of similar shape and charge. Conservative substitutions are well known in the art and include, for example, the changes of: alanine to serine; arginine to lysine; asparagine to glutamine or histidine; aspartate to glutamate; cysteine to serine; glutamine to asparagine; glutamate to aspartate; glycine to proline; histidine to asparagine or glutamine; isoleucine to leucine or valine; leucine to valine or isoleucine; lysine to arginine, glutamine, or glutamate; methionine to leucine or

1002540614.4

isoleucine; phenylalanine to tyrosine, leucine or methionine; serine to threonine; threonine to serine; tryptophan to tyrosine; tyrosine to tryptophan or phenylalanine; and valine to isoleucine or leucine.

“Insertions” add extra amino acids to the interior (not the amino- or carboxyl-terminal ends) of the subject polypeptide. Insertions include amino acids encoded by exons that are alternatively spliced into a polypeptide, such as the splicing variants shown in FIGURES 8 and 9. “Deletions” diminish the overall size of the polypeptide by removal of amino acids from the interior or either end of the polypeptide. In one embodiment, deletions remove less than about 30% of the size of the subject molecule. Other preferred deletions include naturally occurring splicing variants of a Pot1 protein, such as those described above. These variants may be fragments of the size the full-length protein, which may be considerably smaller than 30% the size of the full-length protein.

“Additions,” like insertions, also add to the overall size of the protein; however, instead of being made within the molecule, they are made on the N- or C-terminus of the encoded protein. Unlike deletions, additions may be of virtually any size; however, preferred additions do not exceed about 100% of the size of the native molecule. “Additions” also encompass adducts to the amino acids of the native molecule.

In general, both the DNA and protein molecules of the invention can be defined with reference to “sequence identity.” As used herein, “sequence identity” refers to a comparison made between two molecules using standard algorithms well-known in the art. Although any sequence algorithm can be used to define “sequence identity,” for clarity, the present invention defines identity with reference to the Smith-Waterman algorithm, where the open reading frame generally is used as the reference sequence to define the percentage identity of polynucleotide homologues over its length. When “sequence identity” is used with reference to a polypeptide, the designated polypeptide is used as a reference sequence over its length.

P002540614.4

The choice of parameter values for matches, mismatches, and inserts or deletions is arbitrary, although some parameter values have been found to yield more biologically realistic results than others. One preferred set of parameter values for the Smith-Waterman algorithm is set forth in the "maximum similarity segments" approach, which uses values of 1 for a matched residue and $\frac{1}{3}$ for a mismatched residue (a residue being either a single nucleotide or a single amino acid). Insertions and deletions ("indels"), x , are weighted as:

$$x_k = 1 + k/3,$$

where k is the number of residues in a given insert or deletion (Waterman, *Bulletin of Mathematical Biology* 46:473-500 (1984)).

Polynucleotides of the invention.

Polynucleotides of the invention are those that encode Pot1 proteins or their fragments and derivatives. These polynucleotides include those that encode SpPot1 polypeptides. An *S. pombe* genomic DNA sequence is described by the Sanger Centre as part of cosmid clone c26H5, having accession number SPAC26H5 (SEQ ID NO:7). This sequence contains an upstream promoter region, a coding region with two introns, and a downstream region that contains a terminator. Both upstream and downstream regions may play a role in the regulation of SpPot1p expression. The introns can be alternatively spliced, as described above (SEQ ID NOS:8 and 10). Preferred polynucleotides are non-genomic; *i.e.*, they correspond to transcripts from genomic DNA. An example of non-genomic DNA is a mRNA or cDNA encoding the polypeptides of SEQ ID NO: 9 or SEQ ID NO:11.

The polynucleotides of the invention also include those that encode a hPot1p and its variants and fragments. A partial genomic clone is described for human *POT1*, having accession number AC004925 (SEQ ID NO:18). This partial genomic clone contains nine exons, shown diagrammatically in FIGURE 10G. Of these exons, at least exons 5 and 10 can be alternatively spliced (compare SEQ ID NOS:12, 14, and 16). Various cDNA sequences encoding full-length hPot1p have

been described: FLJ10368 (submitted 22 Feb. 2000), FLJ11073 (submitted 22 Feb. 2000), FLJ12518 (submitted 29 Sept. 2000), BC002923 (submitted 5 Feb. 2001), and NM_015450 (submitted 26 Feb. 2001). Various other partial cDNA sequences and ESTs that encode portions of hPot1 protein also have been described: FLJ22851 (submitted 29 Sept. 2000), AL050120 (submitted 18 Feb. 2000). Of the *hPOT1* polynucleotides presently described, only the *hPOT1* cDNA of SEQ ID NO:12 closely resembles the sequences described in FLJ10368, FLJ11073, and FLJ12518.

The invention also provides a nucleic acid molecule having a sequence complementary to one of the above sequences. Such isolated nucleic acid molecules are useful as probes for gene mapping by *in situ* hybridization with chromosomes. They are particularly useful for detecting transcription of a *POT1* gene in human tissue, or transcripts of naturally occurring homologues that may themselves be therapeutically useful.

The polynucleotides of the invention may also be useful for detecting transcripts of naturally occurring *POT1* variants occurring in disease states. The present polynucleotides thus may have diagnostic application in differentiating normal and abnormal genes, based on differential hybridization, as discussed in more detail below. Alternatively, a diagnostic application may include differentiating abnormally high or low levels of expression of a normal gene.

Isolated nucleic acid molecules of the present invention include nucleic acid molecules comprising the coding sequence for a Pot1 protein, and nucleic acid molecules which comprise a nucleotide sequence substantially different from those described above but which, due to the degeneracy of the genetic code, still encode at least one Pot1 protein as described and enabled herein. Of course, the genetic code is well-known in the art. Thus, it would be routine for one skilled in the art to generate such degenerate nucleic acid variants that code for specific Pot1 proteins of the present invention. See, e.g., Ausubel, *et al.*

The term “hybridization” refers to formation of double stranded polynucleotides through complementary nucleotide base pairing. High stringency

hybridization occurs at a temperature between about 65 °C and 70 °C in a hybridization solution of 6X SSC, 0.5% SDS, 5X Denhardt's solution and 100 μ g of non-specific carrier DNA. The preferred probe is 100 bases selected from contiguous bases of the polynucleotide sequence set forth in SEQ ID NO:1. A high stringency wash solution contains the equivalent in ionic strength of less than about 0.2X SSC and 0.1 % SDS, with a preferred stringent solution containing about 0.1X SSC and 0.1 % SDS. High stringency washing conditions comprise washing with 2X SSC with 0.05 % SDS five times at room temperature, then washing with 0.1X SSC with 0.1 % SDS at 68 °C for 1 h. Blots containing the hybridized, labeled probe are exposed to film for one to three days.

“Isolated” nucleic acid molecules are removed from their native or naturally occurring environment. For example, recombinant nucleic acid molecules in a vector and/or a host cell are considered isolated for the purposes of the present invention. Isolated RNA molecules include *in vivo* or *in vitro* RNA transcripts of the nucleic acid molecules of the present invention. Isolated nucleic acid molecules according to the present invention further include such molecules produced synthetically or purified from cells containing such nucleic acids, where the nucleic acid is in other than a naturally occurring form. Isolated nucleic acid molecules include genomic DNA that has been removed from the chromosome in which it occurs naturally.

Vectors of the invention.

The term “vector” refers to a nucleic acid compound used for introducing exogenous nucleic acid into host cells. A vector comprises a nucleotide sequence which may encode one or more polypeptide molecules. Plasmids, cosmids, viruses, and bacteriophages, in a natural state or which have undergone recombinant engineering, are non-limiting examples of commonly used vectors to provide recombinant vectors comprising at least one desired isolated nucleic acid molecule.

The term “promoter” refers to a nucleic acid sequence that directs the initiation of transcription. An inducible promoter is one that is regulated by environmental signals, such as carbon source, heat, or metal ions.

“Host cell” refers to any eukaryotic, prokaryotic, or other cell that is suitable for propagating and/or expressing an isolated nucleic acid that is introduced into the host cell by any suitable means known in the art. The cell can be part of a tissue or organism, isolated in culture or in any other suitable form.

The present invention further provides recombinant expression cassettes comprising a nucleic acid of the present invention, and operably linked to transcriptional initiation regulatory sequences that will direct the transcription of the polynucleotide in the intended host cell. Both heterologous and endogenous promoters can be employed to direct expression. These promoters can also be used, for example, in recombinant expression cassettes to drive expression of antisense nucleic acids to reduce Pot1p content in a desired tissue.

In some embodiments, isolated nucleic acids which serve as promoter or enhancer elements can be introduced in the appropriate position (generally upstream) of a non-heterologous form of a polynucleotide of the present invention so as to up or down regulate expression of a polynucleotide of the present invention. For example, endogenous promoters can be altered *in vivo* by mutation, deletion, and/or substitution. Suitable promoters include the phage lambda PL promoter, the *E. coli lac, trp* and *tac* promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination and, in the transcribed region, a ribosome binding site for translation. The coding portion of the mature transcripts expressed by the constructs will preferably include a translation initiation codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

The polynucleotides can optionally be joined to a vector containing a selectable marker for propagation in a host. Such markers include, *e.g.*,

002540614.4

dihydrofolate reductase or neomycin resistance for eukaryotic cell culture and tetracycline or ampicillin resistance genes for culturing in *E. coli* and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium* cells; fungal cells, such as yeast cells; insect cells such as *Drosophila S2* and *Spodoptera Sf9* cells; animal cells such as CHO, COS and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art. Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from Qiagen; pBS vectors, Phagescript vectors, Bluescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan. Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection or other methods. Such methods are described in many standard laboratory manuals, such as Sambrook, *supra*, Chapters 1-4 and 16-18; Ausubel, *supra*, Chapters 1, 9, 13, 15, 16.

Recombinant protein expression.

The polypeptide can be expressed in a modified form, such as a fusion protein, and can include not only secretion signals, but also additional heterologous functional regions. For instance, a region of additional amino acids, particularly charged amino acids, can be added to the N-terminus of a polypeptide to improve stability and persistence in the host cell, during purification, or during subsequent handling and storage. Also, peptide moieties can be added to a polypeptide to facilitate purification. Such regions can be removed prior to final preparation of a polypeptide. The addition of peptide moieties to polypeptides to engender secretion

or excretion, to improve stability and to facilitate purification, among others, are familiar and routine techniques in the art. Such methods are described in many standard laboratory manuals, such as Sambrook, *supra*, Chapters 17.29-17.42 and 18.1-18.74; Ausubel, *supra*, Chapters 16, 17 and 18.

A Pot1 polypeptide can be recovered and purified from recombinant cell cultures by well known methods. Polypeptides of the present invention include naturally purified products, products of chemical synthetic procedures, and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect and mammalian cells. Polypeptides of the invention can also include an initial modified methionine residue, in some cases as a result of host-mediated processes. The monitoring of the purification process can be accomplished by DNA-binding activity assays, Western blot techniques, radioimmunoassay, or other standard immunoassay techniques. These methods are described in many standard laboratory manuals, such as Sambrook, *supra*, Chapters 17.37-17.42; Ausubel, *supra*, Chapters 10, 12, 13, 16, 18 and 20.

Antibodies of the invention.

Antibodies raised against the proteins and protein fragments of the invention also are contemplated by the invention. In particular, the invention contemplates antibodies raised against Pot1p, and variants thereof. Described below are antibody products and methods for producing antibodies capable of specifically recognizing one or more epitopes of the presently described proteins and their derivatives. Antibodies include, but are not limited to polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, single chain antibodies including single chain Fv (scFv) fragments, Fab fragments, F(ab')₂ fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, epitope-binding fragments, and humanized forms of any of the above.

As known to one in the art, these antibodies may be used, for example, in the detection of a target protein in a biological sample. They also may be utilized as part

P002540614.4

of treatment methods, and/or may be used as part of diagnostic techniques whereby patients may be tested for abnormal levels or preferably for the presence of abnormal forms of the proteins.

In general, techniques for preparing polyclonal and monoclonal antibodies as well as hybridomas capable of producing the desired antibody are well known in the art (Campbell, A.M., *Monoclonal Antibody Technology: Laboratory Techniques in Biochemistry and Molecular Biology*, Elsevier Science Publishers, Amsterdam, The Netherlands (1984); St. Groth et al., *J. Immunol. Methods* 35:1-21 (1980); Kohler and Milstein, *Nature* 256:495-497 (1975)), the trioma technique, the human B-cell hybridoma technique (Kozbor et al., *Immunology Today* 4:72 (1983); Cole et al., in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc. (1985), pp. 77-96).

i) Polyclonal antibodies.

Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of animals immunized with an antigen, such as an inventive protein or an antigenic derivative thereof. Polyclonal antiserum, containing antibodies to heterogeneous epitopes of a single protein, can be prepared by immunizing suitable animals with the expressed protein described above, which can be unmodified or modified, as known in the art, to enhance immunogenicity. Immunization methods include subcutaneous or intraperitoneal injection of the polypeptide.

Effective polyclonal antibody production is affected by many factors related both to the antigen and to the host species. For example, small molecules tend to be less immunogenic than others and may require the use of carriers and/or adjuvant. In addition, host animal response may vary with site of inoculation. Both inadequate or excessive doses of antigen may result in low titer antisera. In general, however, small doses (high ng to low µg levels) of antigen administered at multiple intradermal sites appears to be most reliable. Host animals may include but are not limited to rabbits, mice, and rats, to name but a few. An effective immunization protocol for rabbits can be found in Vaitukaitis, J. et al., *J. Clin. Endocrinol. Metab.* 33:988-991 (1971).

The protein immunogen may be modified or administered in an adjuvant in order to increase the protein's antigenicity. Methods of increasing the antigenicity of a protein are well known in the art and include, but are not limited to coupling the antigen with a heterologous protein or through the inclusion of an adjuvant during immunization.

Booster injections can be given at regular intervals, with at least one usually being required for optimal antibody production. The antiserum may be harvested when the antibody titer begins to fall. Titer may be determined semi-quantitatively, for example, by double immunodiffusion in agar against known concentrations of the antigen. See, for example, Ouchterlony *et al.*, Chap. 19 in: *Handbook of Experimental Immunology*, Wier, ed, Blackwell (1973). Plateau concentration of antibody is usually in the range of 0.1 to 0.2 mg/ml of serum (about 12 μ M). The antiserum may be purified by affinity chromatography using the immobilized immunogen carried on a solid support. Such methods of affinity chromatography are well known in the art.

Affinity of the antisera for the antigen may be determined by preparing competitive binding curves, as described, for example, by Fisher, Chap. 42 in: *Manual of Clinical Immunology*, second edition, Rose and Friedman, eds., Amer. Soc. For Microbiology, Washington, D.C. (1980).

ii) Monoclonal antibodies.

Monoclonal antibodies (MAbs), are homogeneous populations of antibodies to a particular antigen. They may be obtained by any technique that provides for the production of antibody molecules by continuous cell lines in culture or *in vivo*. MAbs may be produced by making hybridomas, which are immortalized cells capable of secreting a specific monoclonal antibody.

Monoclonal antibodies to any of the proteins, peptides and epitopes thereof described herein can be prepared from murine hybridomas according to the classical method of Kohler, G. and Milstein, C., *Nature* 256:495-497 (1975) (and U.S. Patent No. 4,376,110) or modifications of the methods thereof, such as the human B-cell hybridoma technique (Kosbor *et al.*, 1983, *Immunology Today* 4:72; Cole *et al.*, 1983,

Proc. Natl. Acad. Sci. USA 80: 2026-2030), and the EBV-hybridoma technique (Cole *et al.*, 1985, MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96).

In one method a mouse is repetitively inoculated with a few micrograms of the selected protein over a period of a few weeks. The mouse is then sacrificed, and the antibody producing cells of the spleen are isolated. The spleen cells are fused, typically using polyethylene glycol, with mouse myeloma cells, such as SP2/0-Ag14 myeloma cells. The excess, unfused cells are destroyed by growth of the system on selective media comprising aminopterin (HAT media). The successfully fused cells are diluted, and aliquots are plated to microliter plates where growth is continued. Antibody-producing clones (hybridomas) are identified by detection of antibody in the supernatant fluid of the wells by immunoassay procedures. These include ELISA, as originally described by Engvall, *Meth. Enzymol.* 70:419 (1980), western blot analysis, radioimmunoassay (Lutz *et al.*, *Exp. Cell Res.* 175:109-124 (1988)) and modified methods thereof.

Selected positive clones can be expanded and their monoclonal antibody product harvested for use. Detailed procedures for monoclonal antibody production are described in Davis, L. *et al.* BASIC METHODS IN MOLECULAR BIOLOGY, Elsevier, New York. Section 21-2 (1989). The hybridoma clones may be cultivated *in vitro* or *in vivo*, for instance as ascites. Production of high titers of mAbs *in vivo* makes this the presently preferred method of production. Alternatively, hybridoma culture in hollow fiber bioreactors provides a continuous high yield source of monoclonal antibodies.

The antibody class and subclass may be determined using procedures known in the art (Campbell, A.M., *Monoclonal Antibody Technology: Laboratory Techniques in Biochemistry and Molecular Biology*, Elsevier Science Publishers, Amsterdam, The Netherlands (1984)). MAbs may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. Methods of purifying monoclonal antibodies are well known in the art.

iii) Antibody derivatives and fragments.

Fragments or derivatives of antibodies include any portion of the antibody which is capable of binding the target antigen, or a specific portion thereof. Antibody fragments specifically include $F(ab')_2$, Fab, Fab' and Fv fragments. These can be generated from any class of antibody, but typically are made from IgG or IgM. They may be made by conventional recombinant DNA techniques or, using the classical method, by proteolytic digestion with papain or pepsin. See CURRENT PROTOCOLS IN IMMUNOLOGY, chapter 2, Coligan *et al.*, eds., (John Wiley & Sons 1991-92).

$F(ab')_2$ fragments are typically about 110 kDa (IgG) or about 150 kDa (IgM) and contain two antigen-binding regions, joined at the hinge by disulfide bond(s). Virtually all, if not all, of the Fc is absent in these fragments. Fab' fragments are typically about 55 kDa (IgG) or about 75 kDa (IgM) and can be formed, for example, by reducing the disulfide bond(s) of an $F(ab')_2$ fragment. The resulting free sulfhydryl group(s) may be used to conveniently conjugate Fab' fragments to other molecules, such as detection reagents (*e.g.*, enzymes).

Fab fragments are monovalent and usually are about 50 kDa (from any source). Fab fragments include the light (L) and heavy (H) chain, variable (V_L and V_H , respectively) and constant (C_L and C_H , respectively) regions of the antigen-binding portion of the antibody. The H and L portions are linked by an intramolecular disulfide bridge.

Fv fragments are typically about 25 kDa (regardless of source) and contain the variable regions of both the light and heavy chains (V_L and V_H , respectively). Usually, the V_L and V_H chains are held together only by non-covalent interacts and, thus, they readily dissociate; however, they have the advantage of small size and they retain the same binding properties of the larger Fab fragments. Accordingly, methods have been developed to crosslink the V_L and V_H chains, using, for example, glutaraldehyde (or other chemical crosslinkers), intermolecular disulfide bonds (by incorporation of cysteines) and peptide linkers.

Other antibody derivatives include single chain antibodies (U.S. Patent 4,946,778; Bird, *Science* 242:423-426 (1988); Huston *et al.*, *Proc. Natl. Acad. Sci. USA* 85:5879-5883 (1988); and Ward *et al.*, *Nature* 334:544-546 (1989)). Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain Fv (scFv).

One preferred method involves the generation of scFvs by recombinant methods, which allows the generation of Fvs with new specificities by mixing and matching variable chains from different antibody sources. In a typical method, a recombinant vector would be provided which comprises the appropriate regulatory elements driving expression of a cassette region. The cassette region would contain a DNA encoding a peptide linker, with convenient sites at both the 5' and 3' ends of the linker for generating fusion proteins. The DNA encoding a variable region(s) of interest may be cloned in the vector to form fusion proteins with the linker, thus generating a scFv.

In an exemplary alternative approach, DNAs encoding two Fvs may be ligated to the DNA encoding the linker, and the resulting tripartite fusion may be ligated directly into a conventional expression vector. The scFv DNAs generated any of these methods may be expressed in prokaryotic or eukaryotic cells, depending on the vector chosen.

Antibody fragments that recognize specific epitopes may be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')₂ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab)₂ fragments. Alternatively, Fab expression libraries may be constructed (Huse *et al.*, 1989, *Science*, 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

Derivatives also include "chimeric antibodies" (Morrison *et al.*, *Proc. Natl. Acad. Sci.*, 81:6851-6855 (1984); Neuberger *et al.*, *Nature*, 312:604-608 (1984); Takeda *et al.*, *Nature*, 314:452-454 (1985)). These chimeras are made by splicing the

DNA encoding a mouse antibody molecule of appropriate specificity with, for instance, DNA encoding a human antibody molecule of appropriate specificity. Thus, a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region. These are also known sometimes as "humanized" antibodies and they offer the added advantage of at least partial shielding from the human immune system. They are, therefore, particularly useful in therapeutic *in vivo* applications.

iv) Labeled antibodies.

The present invention further provides the above-described antibodies in detectably labeled form. Antibodies can be detectably labeled through the use of radioisotopes, affinity labels (such as biotin, avidin, etc.), enzymatic labels (such as horseradish peroxidase, alkaline phosphatase, etc.), fluorescent labels (such as FITC or rhodamine, etc.), paramagnetic atoms, etc. Procedures for accomplishing such labeling are well-known in the art, for example see (Sternberger *et al.*, *J. Histochem. Cytochem.* 18:315 (1970); Bayer *et al.*, *Meth. Enzym.* 62:308 (1979); Engval *et al.*, *Immunol.* 109:129 (1972); Goding, *J. Immunol. Meth.* 13:215 (1976)). The labeled antibodies of the present invention can be used for *in vitro*, *in vivo*, and *in situ* diagnostic assays.

v) Immobilized antibodies.

The foregoing antibodies also may be immobilized on a solid support. Examples of such solid supports include plastics such as polycarbonate, complex carbohydrates such as agarose and sepharose, acrylic resins and such as polyacrylamide and latex beads. Techniques for coupling antibodies to such solid supports are well known in the art (Weir *et al.*, "Handbook of Experimental Immunology" 4th Ed., Blackwell Scientific Publications, Oxford, England, Chapter 10 (1986); Jacoby *et al.*, *Meth. Enzym.* 34 Academic Press, N.Y. (1974)). The immobilized antibodies of the present invention can be used for *in vitro*, *in vivo*, and *in situ* assays as well as for immunoaffinity purification of the proteins of the present invention.

Pharmaceutical compositions comprising a POT1 gene.

Pharmaceutical compositions comprising polynucleotides encoding functional Pot1 polypeptides of the invention are those useful for gene therapy to cause the overexpression of functional Pot1 polypeptides in cells in which chromosome stabilization is desired, or the overexpression of a variant Pot1 polypeptide with dominant negative interference activity in cells in which chromosome destabilization is desired.

Overexpression of *POT1* in a cell may be accomplished by transfecting a cell with a *POT1* polynucleotide. The *POT1* polynucleotide generally is a component on an expression vector of the invention, defined above. The vector may be delivered to a cell by transfection of a cell *ex vivo*, followed by selection and cloning of transfected cells expressing the *POT1* nucleotide and then by administration of the stably transfected cells to an individual in need of the modified cells.

Alternatively, the *POT1* polynucleotide may be delivered to a cell or a population of cells in an individual. Various methods of introducing exogenous genes into cells *in vivo* are known in the art. See Rosenberg *et al.*, *Science* 242:1575-1578 (1988) and Wolff *et al.*, *PNAS* 86:9011-9014 (1989), which are incorporated herein by reference. A listing of suitable vectors is set forth in Hodgson, *Bio/Technology* 13: 222 (1995), which is incorporated by reference. One example of a suitable vector is a cationic liposome, such as DC-Chol/DOPE liposome, which is an appropriate vehicle to deliver DNA to a wide range of tissues through intravenous injection of DNA/cationic liposome complexes. See Caplen *et al.*, *Nature Med.* 1:39-46 (1995) and Zhu *et al.*, *Science* 261:209-211 (1993), herein incorporated by reference.

Viral vector-mediated gene transfer is also a suitable method for the introduction of the vector into a target cell. Appropriate viral vectors include adenovirus vectors and adeno-associated virus vectors, retrovirus vectors and herpesvirus vectors. Adenoviruses are linear, double stranded DNA viruses complexed with core proteins and surrounded by capsid proteins. The common serotypes 2 and 5,

002540614.4

which are not associated with any human malignancies, are typically the base vectors. By deleting parts of the virus genome and inserting the desired gene under the control of a constitutive viral promoter, the virus becomes a replication-deficient vector capable of transferring the exogenous DNA to differentiated, non-proliferating cells. To enter cells, the adenovirus interacts with specific receptors on the cell surface, and the adenovirus surface proteins interact with the cell surface integrins. The virus penton-cell integrin interaction provides the signal that brings the exogenous gene-containing virus into a cytoplasmic endosome. The adenovirus breaks out of the endosome and moves to the nucleus, the viral capsid falls apart, and the exogenous DNA enters the cell nucleus where it functions, in an epichromosomal fashion, to express the exogenous gene. Detailed discussions of the use of adenoviral vectors for gene therapy can be found in Berkner, *Biotechniques* 6:616-629 (1988) and Trapnell, *Advanced Drug Delivery Rev.* 12:185-199 (1993), which are herein incorporated by reference. Adenovirus-derived vectors, particularly non-replicative adenovirus vectors, are characterized by their ability to accommodate exogenous DNA of 7.5 kB, relative stability, wide host range, low pathogenicity in man, and high titers (10^4 to 10^5 plaque forming units per cell). See Stratford-Perricaudet *et al.*, *PNAS* 89:2581 (1992).

Pharmaceutical compositions may be formulated with one or more physiologically acceptable carriers or excipients. In one embodiment, the composition is formulated for injection. Long acting formulations are generally known in the art and can be adapted to the administration of a *POT1* polynucleotide. Such compositions may be in the form of suspensions, solutions, emulsions in vesicles, or any other form known in the art. Additional suspending, stabilizing, or dispersing agents may be added as necessary. Alternatively, the active ingredient may be in the form of a powder for reconstitution prior to administration.

Diagnostic methods.

The present invention also contemplates methods for diagnosis of human disease. In particular, patients can be screened for the occurrence of cancers, or

likelihood of occurrence of cancers, associated with mutations in the Pot1 protein or with changes in its level of expression. By examining a number of patients in this manner, mutations in the gene that are associated with a malignant cellular phenotype can be identified. In addition, correlation of the nature of the observed mutations with subsequent observed clinical outcomes allows development of prognostic model for the predicted outcome in a particular patient.

Screening for mutations conveniently can be carried out at the DNA level by use of PCR, although the skilled artisan will be aware that many other well known methods are available for the screening. PCR primers can be selected that flank known mutation sites, and the PCR products can be sequenced to detect the occurrence of the mutation. Alternatively, the 3' residue of one PCR primer can be selected to be a match only for the residue found in the unmutated gene. If the gene is mutated, there will be a mismatch at the 3' end of the primer, and primer extension cannot occur, and no PCR product will be obtained. Alternatively, primer mixtures can be used where the 3' residue of one primer is any nucleotide other than the nonmutated residue. Observation of a PCR product then indicates that a mutation has occurred. Other methods of using, for example, oligonucleotide probes to screen for mutations are described, or example, in U.S. Patent No. 4,871,838, which is herein incorporated by reference in its entirety.

Alternatively, antibodies can be generated that selectively bind either mutated or non-mutated Pot1 protein. The antibodies then can be used to screen tissue samples for occurrence of mutations in a manner analogous to the DNA-based methods described above.

The diagnostic methods described above can be used not only for diagnosis and for prognosis of existing disease, but may also be used to predict the likelihood of the future occurrence of disease. For example, clinically healthy patients can be screened for mutations in the Pot1 protein that correlate with later disease onset. Such mutations may be observed in the heterozygous state in healthy individuals. In such cases a single mutation event can effectively disable proper functioning of the gene encoding

the Pot1 protein and induce a transformed or malignant phenotype. This screening also may be carried out prenatally or neonatally.

DNA molecules according to the invention also are well suited for use in so-called "gene chip" diagnostic applications. Such applications have been developed by, *inter alia*, Synteni and Affymetrix. Briefly, all or part of the DNA molecules of the invention can be used either as a probe to screen a polynucleotide array on a "gene chip," or they may be immobilized on the chip itself and used to identify other polynucleotides via hybridization to the surface of the chip. In this manner, for example, related genes can be identified, or expression patterns of the *POT1* gene in various tissues can be simultaneously studied. Such gene chips have particular application for diagnosis of disease, or predisposition to disease, which may be indicated by a change in the level or tissue distribution of *POT1* mRNA or by the presence of a particular *POT1* mRNA species. Suitable chip technology is described for example, in Wodicka *et al.*, *Nature Biotechnology*, 15:1359 (1997) which is hereby incorporated by reference.

Detection of a Pot1 polypeptide.

The presence of a Pot1 protein may be assayed in a biological sample isolated from an individual. Pot1p may be detected in any number of ways commonly known in the art. For example, Pot1p may be detected by a specific interaction with a labeled antibody of the invention. The antibody label allows rapid detection of an immune complex by such well known methods as Western blotting. Formation of an immune complex will be useful in detecting Pot1 proteins with or without biological function. Thus, an immune complex formation will be the preferred mode of detection of a Pot1 protein in a sample from an individual, where the Pot1 protein in the sample is suspected of lacking activity through genetic alteration. Such an assay thus will be useful in a diagnostic method, to detect altered forms of Pot1p.

Alternatively, a Pot1 protein may be assayed by virtue of its biological function. In one embodiment, a sample suspected of containing a Pot1 polypeptide

is exposed to isolated labeled telomeric DNA. A Pot1 protein is then detected by its ability to interact with the telomeric DNA. A convenient method of assaying this interaction is with a gel shift assay, which is well known in the art and used to form the Pot1p-DNA complexes in Example 2.

Pharmaceutical compositions comprising compounds that affect Pot1p activity, and routes of administering the same.

Pharmaceutical compositions comprising compounds that affect Pot1 protein activity can be formulated and administered according to well known methods. These compounds include those small molecule compounds that affect Pot1p binding to telomeric DNA identified by the screening methods of the invention. These compounds may be delivered in a pharmaceutically acceptable carrier vehicle. Suitable vehicles and their formulation are described, for example, in *Remington's Pharmaceutical Sciences* (16th ed., Osol, A., Ed., Mack, Easton PA (1980)).

Pharmaceutical compositions are formulated to provide a "therapeutically effective amount" of a compound that affects the activity of a Pot1 protein. The amount of a compound required for therapeutic efficacy depends on the individual or animal to be treated, and on the precise condition involving a Pot1 protein. The amount actually administered will be optimized to reduce side-effects while having a maximum effect on the activity of a Pot1 protein. Preferably, the amount delivered to the body will be reduced by directed delivery to a population of target cells, where possible.

Pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers or excipients. Thus, the compounds and their physiologically acceptable salts may be formulated for administration by a variety of routes. The compounds may be delivered by parenteral, inhalation or insufflation (either through the mouth or the nose), topical, oral, or depot administration.

DEPARTMENT OF DOCUMENTS

The compounds may be formulated for parenteral administration by injection, *e.g.*, by bolus injection, repeated injections, or continuous infusion. Formulations for injection may be presented in unit dosage form, *e.g.*, in ampules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain agents that aid in suspending, stabilizing or dispersing the active compounds. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, *e.g.*, sterile pyrogen-free water, before use. Instead of injection, the compounds may be administered as an irrigation fluid used to wash areas or organs of the body.

For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, *e.g.*, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, *e.g.* gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, *e.g.*, containing conventional suppository bases such as cocoa butter or other glycerides.

For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (*e.g.*, pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (*e.g.*, lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (*e.g.*, magnesium

stearate, talc or silica); disintegrants (*e.g.*, potato starch or sodium starch glycolate); or wetting agents (*e.g.*, sodium lauryl sulphate). The tablets may be coated or formulated for sustained release by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they maybe presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (*e.g.*, sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (*e.g.*, lecithin or acacia); non-aqueous vehicles (*e.g.*, almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (*e.g.*, methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.

Preferred formulations for oral delivery are described by US Pat. Nos. 5,574,018 and 5,428,023. Biologically active conjugates of a therapeutically useful protein are made with vitamin B₁₂ (VB₁₂) by covalently binding the primary (5') hydroxyl group of the ribose moiety of VB₁₂ to the therapeutic protein. When the resulting conjugate is orally delivered, it binds intrinsic factor (IF) transporter protein in the gastrointestinal tract and is then taken up through the epithelium into the bloodstream, retaining the biological activity of the protein therapeutic. The conjugates may be orally administered in the presence of purified IF, resulting in greater absorption.

WO 93/25221 describes compositions formulated for oral delivery, comprising therapeutic proteins contained in microspheres made of protein and/or synthetic polymer. The microspheres protect their protein contents against gastrointestinal proteases and provide controlled and sustained release of their contents. Microspheres can be designed to pass through the intestinal epithelium into the blood or lymph, and they may be targeted to particular cells or organs. Formulations and methodology useful for targeting orally administered microparticles to various organs are described in EP 531,497, for example.

The present invention, thus generally described, will be understood more readily by reference to the following examples, which are provided by way of illustration and are not intended to be limiting of the present invention.

EXAMPLES

Example 1: Expression and purification of SpPot1p.

SpPot1p containing N-terminal V5 and His₆-tags was cloned into the pQE30 expression vector (Qiagen), which introduces an additional N-terminal His₆-tag, and expressed in *E. coli* strain M15 (pRep4) using tryptone phosphate media. Following induction (0.8 mM IPTG) for 6 hours at 24°C cells were harvested, resuspended in lysis buffer at pH 8.0 (50 mM NaH₂PO₄; 0.1 M NaCl; 2 mM imidazole; 10 % glycerol; 0.2% Tween20; 5 mM β-mercaptoethanol, 1 mM PMSF) and lysed by the addition of lysozyme (0.5 mg/ml). After 30 min the concentration of NaCl was increased to 0.6 M, genomic DNA was sheared by sonication and cell debris was removed by centrifugation at 10,000 g for 30 min. The supernatant was incubated with Ni-NTA resin (Qiagen) at 4°C for 90 min, which was then loaded onto a column and washed sequentially with P buffer (50 mM NaH₂PO₄; 600 mM NaCl; 10 % glycerol; 0.2% Tween20; 5 mM β-mercaptoethanol) containing increasing concentrations of imidazole. Pot1p eluted around 90 mM imidazole. Pot1 containing fractions were dialysed against T buffer (50 mM Tris/HCl pH 8.0; 10% glycerol; 0.5 mM EDTA; 0.5 mM DTT) containing 0.2 M KCl and Pot1p was further purified on a Q-sepharose column (Pharmacia) using a linear gradient of KCl (0.2 M – 1 M). Pot1p eluted around 0.5M KCl, was dialysed against T buffer plus 0.2 M KCl and stored in aliquots at -80°C.

Example 2: DNA-binding specificity of SpPot1p.

C-strand (CGTAACCGTAACCCTGTAACCTGTAACCTGTAACCGTG-TAACCT)
TAACC) and G-strand (GGTTACACGGTTACAGGTTACAGGTTACAG-

Sub A5

GGTTACGGTTACG) were 5' 32 P-labeled using T4 polynucleotide kinase and γ - 32 P-ATP. Duplex DNA was generated by annealing equimolar amounts of radiolabeled C-strand and unlabelled G-strand. Binding reactions (10 μ l) were carried out in 25 mM HEPES (pH 7.5), 1 mM EDTA, 50 mM NaCl, 5% glycerol, and 2.5 μ M PBoli109 (CCGTAAGCATTCAATTGGAATTGAGCTCGTTTCGA) as non-specific competitor. Pot1p (50 ng) was incubated with the indicated DNA substrates (1 ng) for 15 min at 20°C. Complexes were analyzed by electrophoresis at 4°C through a 4-20% TBE gel (Invitrogen) run at 150 V for 80 min. The Pot1p-DNA complex is indicated by an open arrow in FIGURE 3A. FIGURE 3B shows the same experiment except that the added protein (100 ng) contained truncated Pot1p as well as full length protein. Truncated Pot1p-DNA complex is indicated by a closed arrow.

TOEPLITZ 032004

Example 3: Substrate specificity of SpPot1p and hPot1p.

FIGURE 6A shows binding of SpPot1p to radiolabeled *S. pombe* and human G-strand DNAs. FIGURE 6B shows binding of SpPot1p (50 ng) to radiolabeled G-strand (15 pg or 1.5 fmol) in the presence of 10-, 100-, and 1000-fold excess of unlabeled *S. pombe*, human or *O. nova* G-strand. FIGURE 6C shows binding of hPot1p to radiolabeled *S. pombe* and human G-strand DNAs. FIGURE 6D shows binding of hPot1p to radiolabeled human G-strand DNA under same conditions as in FIGURE 6B.

Example 4: Cloning of the hPOT1 gene.

Sub A6

Oligos PBoli164T (TTCAGATGTTATCTGTCAATCAGAACCTG) and PBoli194B (GAACACTGTTACATCCATAGTGATGTATTGTTCC) were used to amplify a 614 bp fragment of *hPOT1* from multiple tissue cDNA panels (Clontech) with Advantage 2 Polymerase mix in the buffer supplied by Clontech. Cycling parameters of touch-down PCR were 94°C for 5 s, 68°C for 120 s (32 cycles). The gene encoding glyceraldehyde phosphate dehydrogenase (*GAPDH*) was used as a

positive control for the integrity of the cDNA sample and was amplified for 26 cycles with primers TGAAGGTEGGAGTCAACGGATTGGT and CATGTGGGCCAT-GAGGTCTACCAC.

hPOT1 was PCR amplified from ovary cDNA and cloned into a pQE30 expression vector. Recombinantly expressed hPot1p (carrying an N-terminal His₆-tag) was purified from *E. coli*. The protein was purified over Ni-NTA resin under the same conditions as SpPot1p. The human protein eluted at around 135 mM imidazole.

The description, specific examples, and data, while indicating exemplary embodiments, are given by way of illustration and are not intended to limit the present invention. Various changes and modifications within the present invention will become apparent to the skilled artisan from the disclosure, and thus are considered part of the invention.